Narrow Results

BioScience Managers banks on growth of anti-infectives market.

Rodin Therapeutics applies insights of epigenetics to neurological disorders.

LBT Innovations finalizes joint venture to drive global production of world-class automated diagnostics technology.

Phylogica expands collaborations with Janssen for peptide-drug conjugates.

Immune Design and Medicago announce license agreement and collaboration to develop novel adjuvanted pandemic influenza vaccines.

Bayat Foundation inaugurates new pediatric critical care facility at Indira Gandhi Hospital in Kabul.

Human African trypanosomiasis (HAT), a fatal infection caused by Trypanosoma brucei (T. brucei) is considered as a neglected disease in the tropical areas, and newer agents with unique mechanism of action are urgently needed. In this work, 65 Imidazopyridine analogues from known literature were selected for building statistically robust genetic algorithm (GA) based QSAR models. Furthermore, values for the various cross-validation properties supported its statistical robustness (model 1, $R_{\mathrm{\text{tr}}}^2=0.8537$, RMSE${}_{\mathrm{\text{cv}}}=0.3586$, MAE${}_{\mathrm{\text{cv}}}=0.2642$, CCC${}_{\mathrm{\text{cv}}}=0.8953$, and $Q_{\mathrm{\text{LMO}}}^2=0.7887$). Our in silico ADMET analysis revealed that a designed molecule, S10 may act as potent lead (T. brucei, pEC${}_{50}$ ($\mu$M), $\mathrm{\text{predicted}}=8.200$) with better pharmacokinetics, no carcinogenicity, class III acute oral toxicity, minimal OCT1 and OCT2 inhibitions and no eye corrosion profiles. Our molecular docking analysis (on 42 drug targets) for a dataset and designed molecules demonstrated higher binding affinity of Imidazopyridine analogues with T. brucei farnesyl diphosphate synthase (TbFPPS) (PDB id: 2I19). This observation was further supported by 100ns molecular dynamics analysis retaining better stability of complex. Thus, imidazopyridine analogues would provide a promising scaffold for the development of anti-HAT agents.